PharmExec
CONTINUE TO SITE >

OR WAIT 15 SECS

John Fox

Articles

3 Reasons US Payers Will Make 2021 a Banner Year for Biosimilars

Following a year which saw a 143% increase in launched biosimilars in the US, here are three reasons why payers will drive adoption further in 2021.